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Abstract
Background: Mortality from cardiovascular disease in Estonia is among the highest in Europe. The reasons for this have 
not been clearly explained. Also, there are no studies available examining outpatient drug utilization patterns in 
patients who suffered from acute myocardial infarction (AMI) in Estonia. The objective of the present study was to 
examine drug utilization in different age and gender groups following AMI in Estonia.
Methods: Patients admitted to hospital with AMI (ICD code I21-I22) during the period of 01.01.2004-31.12.2005 and 
who survived more than 30 days were followed 365 days from the index episode. Data about reimbursed prescriptions 
of beta-blockers (BBs), angiotensin converting enzyme inhibitors/angiotensin II receptor blockers (ACE/ARBs) and 
statins for these patients was obtained from the database of the Estonian Health Insurance Fund. Data were mainly 
analysed using frequency tables and, where appropriate, the Pearson's χ2 test, the Mann-Whitney U-test and the t-test 
were used. A logistic regression method was used to investigate the relationship between drug allocation and age and 
gender. We presented drug utilization data as defined daily dosages (DDD) per life day in four age groups and 
described proportions of different combinations used in men and women.
Results: Four thousand nine hundred patients were hospitalized due to AMI and 3854 of them (78.7%) were treated by 
BBs, ACE/ARBs and/or statins. Of the 4025 inpatients who survived more than 30 days, 3799 (94.4%) were treated at 
least by the one of drug groups studied. Median daily dosages differed significantly between men and women in the 
age group 60-79 years for BBs and ACE/ARBs, respectively. Various combinations of the drugs studied were not 
allocated in equal proportions for men and women, although the same combinations were the most frequently used 
for both genders. The logistic regression analysis adjusted to gender and age revealed that some combinations of 
drugs were not allocated similarly in different age and gender groups.
Conclusions: Most of the patients were prescribed at least one of commonly recommended drugs. Only 40% of them 
were treated by combinations of beta-blockers, ACE inhibitors/angiotensin II receptor blockers and statins, which is 
inconsistent with guideline recommendations in Estonia. Standards of training and quality programs in Estonia should 
be reviewed and updated aiming to improve an adherence to guidelines of management of acute myocardial 
infarction in all age and gender groups.
Background
Beta-blockers (BB), angiotensin-converting enzyme
(ACE) inhibitors (or in case of intolerance, angiotensin II
receptor blockers (ARBs)) and statins are recommended
for most patients after myocardial infarction [1-4].
Underuse of these widely recommended drugs has been
previously reported [5,6] despite the fact that efficacy of
long-term secondary prevention has been confirmed in
many different studies. In addition, non-adherence to
beneficial medications may be a marker of other illnesses
or habits that result in poor outcomes [7]. Moreover, as
well as medication usage (and its success) requiring the
coordination of behaviours of both the prescribing physi-
cian and the patient, it can be used as a marker to reflect
the quality of outpatient care in certain hospitals and/or
countries. No studies have been performed to describe
outpatient drug utilization patterns in patients who suf-
fered from acute myocardial infarction (AMI) in Estonia.
Also, there are no clear factors to explain the very high
cardiovascular morbidity and mortality in Estonia. Thus,
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drug utilization studies in this high risk patient popula-
tion could have an important input into different strate-
gies for improving the quality of secondary prevention.
The aims of our study were to examine drug utilization
in different age and gender groups following acute myo-
cardial infarction in Estonia.
Methods
Estonian health insurance is a social insurance and it
relies on the principle of solidarity. The Estonian Health
Insurance Fund (EHIF) covers the cost of health services
for 94% of Estonian inhabitants covered by this scheme in
case of illness regardless of the amount of social tax paid
by the person concerned. From the beginning of the 1990
s the EHIF database has included information about hos-
pitalization and reimbursement of prescriptions for
insured persons. The validity of AMI diagnoses has been
retrospectively studied - diagnosis of AMI was confirmed
in 93.3% of patients in tertiary care hospitals and in 83.5%
of patients in secondary care hospitals. Any one of the
following criteria satisfied the diagnosis for AMI:
1) typical rise and fall of biochemical markers (troponin
T/I, CK-MB/CK-MB mass) and one of the following: a)
ischemic symptoms; b) development of pathologic Q
waves; c) ECG changes indicative of ischemia; 2) patho-
logic findings of an AMI by autopsy; 3) the presence of
new ST-segment elevation and new chest pain, for those
patients who died and for whom no cardiac markers were
obtained or cardiac marker(s) were negative because of
the short time of attack onset [5].
Beta-blockers, ACE/ARBs and statins can only be pur-
chased by prescription in Estonia, allowing the identifica-
tion of insured people after the prescription has been
reimbursed and the linking of other information included
to the database. Estonian Health Insurance Fund database
studies do not need Ethics Committee approval in Esto-
nia if personal data that could identify individuals is not
included.
For this study the EHIF prepared a list of inpatients
treated for AMI (ICD code I21-I22) during the period of
01.01.2004-31.12.2005. This list was then used to identify
all prescriptions of BBs, ACE/ARBs and statins reim-
bursed to these AMI patients during a 12 month period
(365 days) after the index episode. Mortality data was also
obtained from the Estonian Population Registry for the
12 month period (365 days) after the index episode. The
index episode was defined as the first hospitalization due
to AMI. Data were made available to us such that individ-
uals could not be identified and additional analyses were
performed.
Prescriptions for long-term treatment in Estonia are
provided as a set of three prescriptions for two months
and can be purchased at the time or after every two
months - thus we decided to analyse drug utilization
annually. Drug utilization was analysed by the use of the
defined daily dosages (DDD) concept [8]. The DDD is the
assumed average maintenance dose per day for a drug
used for its main indication in adults. The purpose of the
DDD system is to serve as a tool for drug utilization
research in order to improve quality of drug use. The
total amount of drugs from each drug group reimbursed
during the study period was presented as DDD to mini-
mize confusion from different drugs and doses. This total
was divided by life days per 12 months (365 days) of fol-
low-up period to demonstrate drug utilization. Medicines
reimbursed and DDDs used in calculations were as fol-
lows: metoprolol 150 mg, bisoprolol 10 mg, atenolol 75
mg, nebivolol 5 mg, captopril 50 mg, enalapril 10 mg,
lisinopril 10 mg, perindopril 4 mg, ramipril 2.5 mg, qui-
napril 15 mg, fosinopril 15 mg, zofenopril 30 mg, imi-
dapril 10 mg, losartan 50 mg, eprosartan 600 mg,
valsartan 80 mg, irbesartan 150 mg, candesartan 8 mg,
telmisartan 40 mg, olmesartan 20 mg, simvastatin 15 mg,
pravastatin 20 mg, fluvastatin 40 mg, atorvastatin 10 mg,
rosuvastatin 10 mg [8]. At least one reimbursed prescrip-
tion for a particular drug group was needed to define a
patient as a particular drug group user or treated patient.
A l l  d r u g s  r e i m b u r s e d  w e r e  c o n s i d e r e d  a s  u s e d  b y  t h e
patient.
Data from patients who survived more than 30 days
after the index episode were used to determine drug utili-
zation.
Statistical analysis
Data were mainly analysed using frequency tables. For
descriptive statistics, the results were given as mean val-
ues with the standard deviation, and for the analysis of
treatment utilization, median dosages with 95% confi-
dence intervals were calculated for selected age groups.
Categorical data were compared with Pearson's χ2 test,
continuous data with the t-test and median dosages were
compared with the Mann-Whitney U-test. A logistic
regression method was used to investigate the relation-
ship between drug allocation and age and gender with
individual drugs and drug combinations used as depen-
dent variables. Results were given as odds ratios and their
95% confidence intervals. Analysis was performed with
statistical software package Stata 11 (Stata, College Sta-
tion, TX, USA).
Results
During the study period, 4900 patients were hospitalized
due to AMI (Table 1). Men comprised more than half of
the patients. The combined mean age (± SD) for men and
women was 69 years (± 11.5). The mean age of the men
was significantly lower than for the women. Eight hun-Marandi et al. BMC Public Health 2010, 10:358
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dred seventy five patients, 407 men (mean age ± SD,
71.06 ± 11.5 years) and 468 women (mean age ± SD, 76.95
± 8.73 years) died within 30 days from index episode.
Closer inspection of the age distribution revealed that
there was a higher proportion of men in the 20-59 years
age group while women were more prevalent in the 80-99
years age group. The age group of 60-79 years included
quite similar proportions of men and women. Hence,
among those who survived more than 30 days, more
patients in the younger age groups were men than
women. The proportion of treated patients was signifi-
cantly different in men and women but this distinction
disappeared after exclusion of patients who died within
the first 30 days (Table 2).
Drug utilization
Of the 4900 inpatients, 3854 (78.7%) were treated by at
least one of BBs, ACE/ARBs and/or statins, whilst no
reimbursed prescriptions were found in the Estonian
Health Insurance Fund database for 1046 (21.3%) patients
during the 365 days after the index episode.
Of the 4025 inpatients who survived more than 30 days,
3799 (94.4%) were treated by at least one of BBs, ACE/
ARBs and/or statins, whilst no reimbursed prescriptions
were found in the Estonian Health Insurance Fund data-
base for 226 (5.6%) patients.
Median daily dosages of BBs, ACE/ARBs and statins are
presented as DDDs with 95% confidence intervals for age
groups and gender in Figure 1. Median dosages of these
medicines were very similar in different age groups,
except in case of BBs for women, but this was due to the
small number of women in the age group of 20-39 years.
Comparison between men and women revealed that the
median daily dosage differed significantly in the age
group of 60-79 years. However, median BB dosages allo-
cated were commonly less than 0.4 DDD per day. A simi-
lar difference was observed for ACE/ARB and also in age
group of 60-79 years, but the median daily dosages were
much higher and mostly exceeded 1 DDD per day. Statins
were allocated similarly for both genders and all age
groups.
The number of patients who were treated by various
combinations of drugs is given in Table 3. Pearson's χ2 test
indicated that the treatments were not allocated in equal
proportions for men and women, although the same
Table 2: Characteristics of patients who survived more than 30 days (n = 4025).
Men Women
Total number, (%) 2365 (85.3) 1660 (78.0)**
Number of deaths, (%) 302 (12.8) 276 (16.6)**
Number of treated patients, (%) 2235 (94.5) 1564 (94.2)
Age (years; mean ± SD) 64.73 ± 11.53 72.66 ± 9.90**
20-39 years, No. (%) 34 (1.44) 4 (0.24)**
40-59 years, No. (%) 740 (31.29) 166 (10.00)**
60-79 years, No. (%) 1383 (58.48) 1075 (64.76)**
80-99 years, No. (%) 208 (8.79) 415 (25.00)**
**P < 0.01 for comparison between men and women.
Age was compared with the t-test, otherwise Pearson's χ2 test was used.
Table 1: Characteristics of all inpatients with acute myocardial infarction in Estonia (n = 4900).
Men Women
Total number of patients, (%) 2772 (56.6) 2128 (43.4)**
Number of deaths, (%) 709 (25.6) 744 (35)**
Number of treated patients, (%) 2260 (81.5) 1594 (74.9)**
Age (years; mean ± SD) 65.66 ± 11.56 73.61 ± 9.81**
20-39 years, No. (%) 36 (1.30) 4 (0.19)**
40-59 years, No. (%) 786 (28.35) 183 (8.60)**
60-79 years, No. (%) 1666 (60.10) 1333 (62.64)
80-99 years, No. (%) 284 (10.25) 608 (28.57)**
**P < 0.01 for comparison between men and women. Age was compared with the t-test, otherwise Pearson's χ2 test was used. Marandi et al. BMC Public Health 2010, 10:358
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combinations were most frequently used for both gen-
ders. The results of logistic regression analysis of allo-
cated drug combinations adjusted to gender and age are
pr ese n t ed in T a bl e  4.  T his  a nal ys is  r eveal ed t ha t  som e
combinations of drugs were not allocated similarly in dif-
ferent age and gender groups.
Discussion
This study was the first one aimed at examining long-
term drug utilization in different age and gender groups
following acute myocardial infarction in Estonia. It was
found that 94.4% of patients admitted to hospital due to
AMI and who survived more than 30 days were reim-
bursed at least one prescription of the widely recom-
mended beta-blockers, ACE inhibitors/ARBs or statins.
The proportion of treated patients was very similar for
men and women, although logistic regression analysis
adjusted for gender and age revealed that some combina-
tions of drugs were not allocated similarly in different age
and gender groups. However, it should be emphasized,
that only 40% of treated patients used medicines from all
of the studied groups during the year. Beta-blockers were
commonly used in moderate doses (the most common
was metoprolol, daily dose 50 mg). This finding is very
similar to those from earlier studies where differences
between routine clinical practice and recommendations
were reported [6,9-12]. Differences between the charac-
teristics of patients included in clinical trials and treated
in everyday practice was suggested as being the main rea-
son for these differences and external validity of data
from clinical trials has been debated [13]. Compared to
Estonian data from 2001 where treatment recommenda-
tions at discharge were reported [5], notable improve-
ments in drug usage were observed; among patients who
survived more than 30 days after hospitalization due to
acute myocardial infarction, more patients used widely
recommended drugs. This could be a result of training
programs being provided to physicians during the time
between the two studies, and of the implementation of
treatment guidelines in clinical practice. However, the
number of patients being prescribed these drugs is still
not consistent with guideline recommendations and
needs further improvement.
A small proportion of patients were not using any rec-
ommended medicines during the study period. In addi-
tion to the expected lack of effect from medicines, other
factors could have influenced this finding, such as the age
of the patients, adverse events during the acute attack and
concomitant diseases. For example, the characteristics of
patients who died during the first 30 days after the attack
are different from those of the total population and the
population who survived more than 30 days - this group
consisted of more women and elderly patients.
Figure 1 Median daily dosages of the treatments in age groups 
for men and women who survived more than 30 days (n = 4025). 
Median daily dosages are presented as DDDs with 95% confidence in-
tervals. DDD, defined daily dosages; ACE/ARB, angiotensin converting 
enzyme inhibitors/angiotensin II receptor blockers. DDDs used were as 
follows - metoprolol 150 mg, bisoprolol 10 mg, atenolol 75 mg, nebiv-
olol 5 mg, captopril 50 mg, enalapril 10 mg, lisinopril 10 mg, perindo-
pril 4 mg, ramipril 2.5 mg, quinapril 15 mg, fosinopril 15 mg, zofenopril 
30 mg, imidapril 10 mg, losartan 50 mg, eprosartan 600 mg, valsartan 
80 mg, irbesartan 150 mg, candesartan 8 mg, telmisartan 40 mg, olm-
esartan 20 mg, simvastatin 15 mg, pravastatin 20 mg, fluvastatin 40 
mg, atorvastatin 10 mg, rosuvastatin 10 mg [8]. **P < 0.01 for compar-
ison between men and women with Mann-Whitney U-test
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The Estonian Myocardial Infarction Registry data
showed 30-day mortality in 2001-2002 as 13.2% in men
and 17.4% in women [14]. The results from our study
indicated that a high level of mortality was still occurring
after acute myocardial infarction in Estonia, despite treat-
ment improvements - 14.7% of men and 22% of women
die during a 30-day period and altogether 25.6% of men
and 35% of women die during the year after an acute
attack. Mortality rates reported elsewhere varied widely
[6,15-17]. A positive relationship between adherence to
evidence-based pharmacotherapy and survival following
AMI has been reported [18,19]. To date, several risk
scores have been suggested to aid treatment decisions.
For example, the GRACE risk score [20] was suggested
for the determination of patients with a high risk of death
and AMI, and to help physicians optimize revasculariza-
Table 3: Combinations of prescribed treatments for men and women who survived more than 30 days (n = 4025).
Treatment combinations Men (%) Women (%)
BB, No. (%) 176 (7.44) 123 (7.41)
ACE/ARB, No. (%) 170 (7.19) 145 (8.73)
Statins, No. (%) 17 (0.72) 12 (0.72)
BB & ACE/ARB, No. (%) 602 (25.45) 525 (31.63)**
BB & statins, No. (%) 130 (5.50) 49 (2.95)**
ACE/ARB and statins, No. (%) 141 (5.96) 63 (3.80)**
BB & ACE/ARB & statins, No. (%) 999 (42.24) 647 (38.98)
No drugs, No. (%) 130 (5.50) 96 (5.78)
Total, No. (%) 2365 (100.00) 1660 (100.00)
BB, beta-blockers; ACE/ARB, angiotensin converting enzyme inhibitors/angiotensin II receptor blockers.
**P < 0.01 for comparison between men and women with Pearson's χ2 test.
Table 4: Relationship between drug allocation and age and gender in patients who survived more than 30 days.
Drug Male
OR
(95% CI)
Female
OR
(95% CI)
20-39 years
OR
(95% CI)
40-59 years
OR
(95% CI)
60-79 years
OR
(95% CI)
80-99 years
OR
(95% CI)
BB 1.00 0.79
(0.61-1.02)
1.00 0.56
(0.17-1.91)
0.97
(0.29-3.19)
1.93
(0.58-6.47)
ACE/ARB 1.00 0.89
(0.70-1.14)
1.00 2.49
(1.67-3.70)**
5.69
(3.66-8.82)**
Statins 1.00 1.19
(0.55-2.57)
1.00 0.88
(0.38-2.06)
0.17
(0.02-1.37)
BB & ACE/ARB 1.00 1.15
(0.99-1.33)
1.00 0.79
(0.37-1.70)
1.21
(0.57-2.57)
1.92
(0.89-4.14)
BB & statins 1.00 0.68
(0.49-0.92)**
1.00 0.66
(0.19-2.21)
0.81
(0.24-2.66)
0.28
(0.08-1.06)
ACE/ARB & statins 1.00 0.63
(0.44-0.89)**
1.00 0.48
(0.18-1.28)
0.32
(0.12-0.84)**
0.19
(0.06-0.58)**
BB & ACE/ARB & statins 1.00 1.21
(1.05-1.39)**
1.00 1.94
(1.00-3.77)
1.02
(0.53-1.96)
0.28
(0.14-0.55)**
**P < 0.05 by logistic regression method.
BB, beta-blockers; ACE/ARB, angiotensin converting enzyme inhibitors/angiotensin II receptor blockers; OR, Odds ratio; CI, confidence intervalMarandi et al. BMC Public Health 2010, 10:358
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tion decisions [21]. Although patient risk profiles can be
among the factors determining treatment decisions and
outcomes [15], the routine scoring of AMI patients is not
common in Estonia. Moreover, there is no evidence of
specific genetic, socioeconomic or other factors which
could explain the high mortality rates after AMI in Esto-
nia. According to recent findings from unpublished data
by Blöndal M et al, improved access to percutaneous cor-
onary interventions during the last few years did not pos-
itively influence the annual mortality rate of patients who
suffered from acute myocardial infarction.
There were a number of limitations to this study. Firstly,
the database that was used does not record data about
patients who are not covered by the Health Insurance
Fund Scheme or prescriptions that are not reimbursed by
the Estonian Health Insurance Fund. Thus, we did not
have data about the medical care of 6% of Estonian inhab-
itants or data about the use of medicines not reimbursed.
However, the proportion of patients and prescriptions
that was not included was too small to affect the results of
this study. Databases of reimbursed prescriptions have
been used in drug utilization studies elsewhere and were
considered to adequately represent real situations.
Secondly, the DDDs that were used can be difficult to
interpret in terms of clinical efficacy. However, as
patients were treated with many different medicines - 4
beta-blockers, 16 ACE/ARBs, 5 statins - it was decided
that the DDD was the simplest way to present drug utili-
zation and to compare drug utilization patterns in differ-
ent age and gender groups.
Thirdly, data about treatment during hospital stays (e.g.
revascularization methods used), concomitant diseases
and other medicines used (e.g. clopidogrel, antiinflamma-
tory drugs, aspirin) was not collected and analysed due to
different reasons. For example, aspirin and some anti-
inflammatory drugs are defined as over-the-counter
(OTC) drugs not included in the Estonian Health Insur-
ance Database. No data on the use of these drugs by post-
AMI patients can be obtained from pharmacies either.
Clopidogrel was not recommended to all AMI patients
during the study period and had limited use due to a
restricted reimbursement policy. Thus, we decided not to
include data about clopidogrel use in our study. Report-
ing of concomitant diseases in the Estonian Health Insur-
ance Fund database is not validated and would also be
misinterpreted due to the implemented financing model
that was partly based on disease-related group methodol-
ogy.
Finally, our data contained no information about
adverse events and intolerances, which could explain our
findings of quite low median daily doses in different drug
groups.
Conclusions
Most of patients who survived 30 days after acute myo-
cardial infarction were prescribed at least one of com-
monly recommended drugs. Only 40% of these patients
were treated with a triple combination of beta-blockers,
ACE inhibitors/angiotensin II receptor blockers and sta-
tins, which is inconsistent with the recommendations of
guidelines in Estonia. Standards of training and quality
programs in Estonia should be reviewed and updated
aiming to improve an adherence to guidelines of manage-
ment of acute myocardial infarction in all age and gender
groups.
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